5 April 2016

Belleville, Ontario – NovaVive Inc., a Canadian immunobiology company, is offering an alternative to antibiotics for the treatment of equine endometritis: Settle®. This product is fully approved by regulators in the U.S. and Australia.

Settle is an immunotherapeutic that used as an aid in the treatment of equine endometritis caused by Streptococcus zooepidemicus, the hardest to treat cause of the disease.

Endometritis is an important disease with significant economic impact to the horse industry, and this non-life threatening condition is a contributing factor in preventing a broodmare from becoming pregnant. It is estimated that up to 43% of broodmares worldwide are affected by endometritis. Mares can be classified as resistant or susceptible according to their ability to clear uterine fluid within 48 hours of breeding or bacterial inoculation. These mares are usually older or barren with a history of endometritis. The most commonly used treatment is antibiotics.

Studies have shown that a single dose of Settle – on its own - can help resolve a broodmare’s uterine infection and the damaging inflammation it causes, resulting in a successful pregnancy.

“Settle is the world’s first and only immunotherapeutic that has received regulatory approval to treat equine endometritis,” said Mr. Graeme McRae, President of NovaVive Inc. “It is approved for both intravenous and intrauterine administration, providing the veterinarian with treatment options.”

About NovaVive Inc.

NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction technology with 4 regulator-approved products. Some of these products have demonstrated the capability of reducing the reliance on antibiotics in the treatment of certain diseases of horses and cattle. The Company’s development plan is to identify additional livestock and companion animal diseases that may be effectively treated with its immunotherapeutic technology platform. For more information about Settle or the Company’s other products, visit www.NovaVive.ca.

For further information, contact:

Graeme McRae, President
Graeme.McRae@NovaVive.ca
Phone: 613-391-3837

or

Jennifer Shea, Vice-President, Investor Relations & Business Development
Jennifer.Shea@NovaVive.ca
Phone: 613-391-2097